Deal marks Merck’s largest acquisition since 2015, expanding its life sciences portfolio with a 36% premium for Bio-Techne shares.
Merck KGaA will acquire Bio-Techne Corporation for $11.3bn, paying $73 per share, a 36% premium over its one-month volume-weighted average price. The offer reflects a 25% premium to Bio-Techne’s last close of $58.88 on June 24.
Bio-Techne, a global life sciences company, reported over $1.2bn in net sales for fiscal 2025 and employs 3,100 people across 34 locations. The acquisition follows Merck’s $17bn purchase of Sigma-Aldrich in 2015, reinforcing its strategy to diversify beyond pharmaceuticals.
Merck stated the deal will bolster its capabilities in drug development, diagnostics, and manufacturing, integrating Bio-Techne’s portfolio of proteins, antibodies, and immunoassay kits.